Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease

Constantine E Kosmas, Andreas Sourlas, Delia Silverio, Peter D Montan, Eliscer Guzman

Abstract
Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide. Currently, it is well established that dyslipidemia is one of the major risk factors leading to the development of atherosclerosis and CVD. Statins remain the standard-of-care in the treatment of hypercholesterolemia and their use has significantly reduced cardiovascular morbidity and mortality. In addition, recent advances in lipid-modifying therapies, such as the development of proprotein convertase subtilisin/kexin type 9 inhibitors, have further improved cardiovascular outcomes in patients with hypercholesterolemia. However, despite significant progress in the treatment of dyslipidemia, there is still considerable residual risk of recurring cardiovascular events. Furthermore, in some cases, an effective therapy for the identified primary cause of a specific dyslipidemia has not been found up to date. Thus, a number of novel pharmacological interventions are under early human trials, targeting different molecular pathways of lipid formation, regulation and metabolism. This editorial aims to discuss the current clinical and scientific data on new promising lipid-modifying therapies addressing unmet needs in CVD, which may prove beneficial in the near future.

Key words: Lipid-modifying therapies; Cardiovascular disease; Dyslipidemia

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Despite significant progress in the treatment of dyslipidemia, there is still considerable residual risk of recurring cardiovascular events. Ongoing research has led to the discovery of several different molecules involved in lipid homeostasis, which can serve as possible targets for new lipid-modifying therapies. Novel medications that have...
MEDICATIONS THAT DECREASE LDL CHOLESTEROL LEVELS

The direct association between plasma LDL-C concentration and the incidence of CVD has been unequivocally proven in many epidemiological studies. Inclisiran is a new, recently developed agent, which targets PCSK9 via a different route, as compared to PCSK9 monoclonal antibodies. Inclisiran, which is administered provided promising results in early human trials include inclisiran, bempedoic acid, seladelpar, CSL-112, apabetalone, volanesorsen, APO(a)-RX, and APO(a)-LRX. Furthermore, several other lipid-lowering agents are being evaluated in ongoing trials. Thus, there is optimism that use of these lipid-lowering medications may in the future lead to a reduction of the residual cardiovascular risk.

INTRODUCTION

Cardiovascular disease (CVD) has consistently been the leading cause of death in the United States from 1950 through 2014[1]. However, a significant decline in premature mortality due to heart disease is projected through 2030 in United States, attributed mainly to sustained declines in smoking, cholesterol and hypertension, which are major risk factors for CVD, as well as to presumed future advances in medical care and treatment[2].

Undoubtedly, lipid-modifying therapies have played a crucial role in the prevention and treatment of major adverse CV events, improving the CV outcomes of patients with dyslipidemia. Statins are the standard-of-care for the treatment of hypercholesterolemia and their use is supported by extensive evidence demonstrating their effectiveness in lowering low density lipoprotein cholesterol (LDL-C) and in reducing CVD risk in both primary and secondary prevention[3]. Furthermore, statins exert a number of pleiotropic cardioprotective effects, including improved endothelial function, reduced vascular inflammation, and reduced platelet adhesion and thrombosis, which also definitely contribute in the reduction of CVD risk[4]. Another recent success story is the development of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9), which cause a 54.0%-62.7% incremental reduction in LDL-C levels when administered on top of statins and are associated with a significant reduction of adverse CV events[5,6]. Certainly, several other lipid-modifying therapies are currently being used in everyday clinical practice, such as fibrates, ezetimibe, bile acid sequestrants and niacin.

However, despite the significant progress made in the treatment of dyslipidemia, there is still considerable residual risk of recurring cardiovascular events[7,8]. Our current pharmacological interventions are able to target a finite only number of lipid pathways. For example, up to date, no specific therapy has been found, which would specifically and significantly improve high-density lipoprotein (HDL) functionality and cholesterol efflux capacity (CEC), leading to a reduction of CVD risk. Moreover, there are many rare, yet important, genetic diseases that cause dyslipidemia and hence premature CVD, for which a specific therapy has not yet been found. In addition, intolerance to certain lipid-lowering medications, especially statins, due to side effects (mostly myalgias and weakness), as well as inability to achieve the LDL-C goal despite use of maximally tolerated dose of statins, are factors that undoubtedly contribute to the residual CVD risk[9].

Given the above, extensive research is being conducted for the development of new drugs that would reduce residual CV risk and address other unmet needs in CVD. Thus, this editorial aims to discuss the current clinical and scientific data on new promising lipid-modifying therapies addressing unmet needs in CVD, which may prove beneficial in the near future.
subcutaneously, is a chemically synthesized small interfering RNA molecule, which targets the hepatic production of PCSK9, as it affects the degradation of mRNA post-transcription, thus preventing translation of PCSK9. ORION-1 was a phase 2, multicenter, double-blind, placebo-controlled, multiple ascending-dose trial of inclisiran, administered in patients at high risk for CVD with elevated plasma LDL-C concentration. Administration of a single or two doses of inclisiran was associated with marked declines in LDL-C and PCSK9 levels, as compared to placebo. The greatest LDL-C reduction (52.6%) was observed in association with the two-dose 300-mg regimen of inclisiran. An ongoing phase 3 clinical trial, ORION-11, is expected to provide more information about the cardioprotective properties of inclisiran and its long-term safety and efficacy. The results of this trial are expected to be available in late 2019.

Undoubtedly, inclisiran is a new promising agent for further reduction of the residual cardiovascular risk in patients with elevated LDL-C. Furthermore, there is optimism that inclisiran only needs to be administered once every 3-6 mo, which would significantly improve compliance and comfort for the patients.

Another novel LDL-C targeting drug, which is currently under clinical trials, is ETC-1002 or bempedoic acid, a dual modulator of hepatic adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK). Inhibition of ACL leads to reduced acetyl coenzyme A (CoA) and hence decreased 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, which is the molecular target of statins. Adding to that, activation of AMPK leads to an inhibitory phosphorylation of HMG-CoA reductase and to improved glucose regulation. In a phase 2a clinical trial, ETC-1002 was shown to be safe and well tolerated and it significantly lowered LDL-C by up to 27% in a dose-dependent manner in patients with hypercholesterolemia. In another phase 2a clinical trial, ETC-1002 not only reduced LDL-C by 43% after 4 wk, but also decreased high sensitivity CRP (hsCRP) by 41% in patients with hypercholesterolemia and type 2 diabetes mellitus without worsening glycemic control. Moreover, ETC-1002 was shown to be effective, causing a significant reduction in LDL-C levels, when administered to patients with statin intolerance or when given as add-on therapy to statin- or ezetimibe-treated patients.

The results of a phase 3 trial with bempedoic acid (CLEAR Wisdom Trial) were very recently presented at the American College of Cardiology 2019 Scientific Sessions. Bempedoic acid (ETC-1002), added to maximally tolerated statin therapy in patients with hypercholesterolemia and high risk for CVD, lowered LDL-C by 17.4% at 12 wk compared to placebo and maintained significant LDL-C reductions for 52 wk. In addition, bempedoic acid decreased hsCRP by 18.7%. There was no worsening of glycemic control in patients with a history of diabetes and the side effect profile of bempedoic acid was similar to that of placebo. No difference was noted for clinical outcomes, although the trial was not powered for this endpoint. Thus, further outcome studies are required to more definitely assess the role of bempedoic acid in reducing CV risk. Notwithstanding, bempedoic acid may in the future provide an additional therapeutic option to safely lower LDL-C in high CV risk patients with elevated LDL-C treated with maximally tolerated dose of statins and other lipid-modifying therapies.

Peroxisome proliferator-activated receptors (PPARs) are molecular sensors that regulate diverse aspects of lipid metabolism, thus playing a crucial role in lipid homeostasis. Three isotypes of PPARs have been described: α (NR1C1), β/δ (NR1C2) and γ (NR1C3). Fibrates are classical PPARα agonists, whereas thiazolidinediones are potent PPARγ agonists. PPARβ/δ agonists are not currently used in clinical practice; however, they have shown promising results in early clinical trials.

Seladelpar or MBX-8025 is a selective PPAR-δ agonist, which has emerged as a promising new agent for the treatment of mixed dyslipidemia. In a multicenter, randomized, double-blind, placebo-controlled study, MBX-8025 was administered to patients with mixed dyslipidemia, alone or in combination with atorvastatin, for 12 wk. In this study, MBX-8025 reduced LDL-C by 18%-43%, triglycerides by 26%-30% and hsCRP by 43%-72%, favorably affecting multiple metabolic parameters. The administration of MBX-8025 was safe and generally well-tolerated. Moreover, MBX-8025 produced substantial reductions in small and very small LDL particles, which translated to reversal of the small dense LDL phenotype in the vast majority of participants. Although these initial results with the use of MBX-8025 appear very promising, further large clinical studies are required to definitely ascertain that the use of MBX-8025 (or another PPARβ/δ agonist) will be truly associated with a reduction in CV risk.
MEDICATIONS THAT INCREASE HDL CHOLESTEROL LEVELS AND/OR FUNCTIONALITY

The inverse association of HDL cholesterol (HDL-C) with future risk of CVD has been unequivocally demonstrated in several epidemiological studies. Although the concept of developing a drug that would raise HDL-C levels and subsequently reduce CV risk exists for many years, no selective HDL-C-raising medication has proven its atheroprotective properties in previous clinical trials. In fact, our current knowledge indicates that HDL functionality plays a much more crucial role in atheroprotection than circulating HDL-C levels[28].

A reconstituted infusible human apolipoprotein A-I (ApoA-I), CSL-112, is under early human trials. In a phase 2a, randomized, double-blind, multicenter, dose-ranging trial, a single intravenous infusion of CSL-112 in patients with stable atherosclerotic disease was shown to be safe and well tolerated. It produced marked and rapid dose-dependent increases in ApoA-I levels (up to 145% increase in the 6.8-g group after 2 h from the time of administration). In addition, total CEC, a key metric of HDL functionality was increased up to 3.1-fold, as compared with placebo[29]. In another phase 2b trial, 4 consecutive weekly infusions of CSL-112, administered to patients with a recent acute myocardial infarction, induced an increase in ApoA-I levels, HDL-C levels, as well as CEC, and preferentially ATP-binding cassette transporter A1 (ABCA1)-dependent CEC, in a dose-dependent manner and with no significant side effects[28]. Given the above, CSL-112 appears to be a very promising new therapeutic intervention for patients with CVD and currently a phase 3 trial is ongoing to assess the potential benefit of CSL-112 in reducing major adverse CV events in patients with acute coronary syndrome. The results of this trial are expected to be available in 2022[30].

Apabepetone or RXV-208 is an orally active small molecule, which increases ApoA-I transcription through an epigenetic mechanism that is mediated by bromodomain and extra-terminal domain (BET) protein 4 (BRD4)[24]. In a multicenter, randomized, double-blind, placebo-controlled study, RXV-208 was administered at varying doses twice daily for 12 wk to statin-treated patients with stable coronary artery disease (CAD). In this study, administration of RXV-208 led to a significant, dose-dependent increase of ApoA-I levels by up to 5.6%. HDL-C levels were also increased by 3.2% to 8.3%, with increasing doses of RXV-208. In addition, there was an increase of the large HDL particles. Transient and reversible elevations in liver transaminases, but with no associated increase in bilirubin levels, were observed in some patients treated with RXV-208[27]. Another study, which retrospectively analyzed the clinical data from two randomized, double-blind, placebo-controlled, similarly designed phase 2b clinical trials of RXV-208 treatment over 6 mo in patients with CAD (SUSTAIN and ASSURE trials), demonstrated a statistically significant increase in HDL-C, ApoA-I, large HDL particles, and average HDL particle size of 7.69%, 10.3%, 30.7%, and 1.16%, respectively, versus placebo. Moreover, a post-hoc analysis showed lower instances of major adverse cardiac events in patients receiving RXV-208[28]. In addition, there is evidence suggesting that RXV-208 may exert a protective effect against the development of type 2 diabetes[29]. Notwithstanding, further studies will be required to better define the role of RXV-208 in the reduction of the risk for CVD.

MEDICATIONS THAT DECREASE TRIGLYCERIDE LEVELS

ApoC-III is another molecule that plays an important regulative role in lipoprotein metabolism. ApoC-III raises plasma triglycerides through inhibition of lipoprotein lipase (LPL), an enzyme essential for the hydrolysis and distribution of triglyceride-rich lipoproteins (TRLs) to extrahepatic tissues, as well as through stimulation of very low-density lipoprotein secretion and via prevention of the hepatic clearance of TRL remnants by the LDL receptor[31]. Elevated plasma triglyceride levels are associated with CVD and clinical studies have clearly shown that non-fasting triglyceride levels are strongly predictive of ischemic events and all-cause mortality, even when differences in plasma HDL-C are taken into account[32]. Epidemiological evidence shows that carriers of loss-of-function mutations of the ApoC-III gene have 39% lower triglycerides, 22% higher HDL-C, and 16% lower LDL-C plasma concentrations. More importantly, their risk of coronary heart disease is reduced by 40%[33].

Given the above, reduction of ApoC-III plasma levels has emerged as a promising therapeutic strategy to decrease risk for CVD. This has led to the development of volanesorsen or ISIS 304801, which is a human antisense oligonucleotide (ASO) that binds to mRNA of the ApoC-III gene and blocks its expression. In a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study, ISIS 304801,
administered as a single agent to patients with hypertriglyceridemia, produced dose-dependent mean reductions in APOC-III levels of up to 79.6% and reductions in triglycerides of up to 70.9%. No safety concerns related to the use of ISIS 304801 were identified in this study.[32] In another study, volanesorsen (ISIS 304801), administered to patients with hypertriglyceridemia, including familial chylomicronemia syndrome, uniformly lowered ApoC-III on ApoB-100, lipoprotein (a) [Lp(a)] and ApoA-I. Thus, it was suggested that volanesorsen may be a potent agent to reduce triglycerides and CV risk mediated by ApoC-III.[33] In addition, there is evidence that volanesorsen may be an especially useful treatment option for patients with hypertriglyceridemia and type 2 diabetes mellitus, as it improves glucose disposal, insulin sensitivity and various integrative markers of diabetes after short treatment[34]. Given the above, volanesorsen appears to be a novel promising therapy for hypertriglyceridemia, which may also decrease the burden associated with certain genetic diseases causing hypertriglyceridemia, such as the familial chylomicronemia syndrome[35]. Notwithstanding, further investigation on the long-term efficacy and safety of volanesorsen is warranted.

MEDICATIONS THAT DECREASE LIPOPROTEIN (a) LEVELS

There is extensive clinical evidence demonstrating that elevated Lp(a) levels is an independent causative risk factor for CVD and aortic stenosis. Current treatments that are being used to decrease Lp(a) include nicotinic acid, aspirin and, in more severe cases, lipoprotein apheresis. Statins may raise Lp(a) by 10%-20% but are also being used in patients with elevated Lp(a) levels only to decrease LDL-C levels and reduce CVD risk. PCKS9 inhibitors have also been shown to reduce Lp(a) levels by approximately 30%, but up to date they have not been approved for the treatment of high Lp(a) levels[36]. The causality of the relation between Lp(a) and CVD is considered significant and hence the concept of developing drugs that effectively reduce Lp(a) exists for many years. However, it is difficult to target Lp(a), as it has no enzymatic activity and it cannot be feasibly targeted with small molecules or monoclonal antibodies. RNA therapeutics, and specifically ASOs, represent an elegant method to reduce circulating Lp(a). Thus, APO(a)-Rx and APO(a)-LRx were developed, which are ASOs that are administered subcutaneously, inhibiting the synthesis of the atherogenic Apo(a), which is primarily synthesized in the liver.[37]

In a randomised, double-blind, placebo-controlled, phase 1 clinical study, participants were treated with a single subcutaneous injection or with six injections of APO(a)-Rx at varying doses. The single injection regimen did not provide any reduction in Lp(a) plasma levels. However, the six injections of APO(a)-Rx resulted in dose-dependent decreases in plasma Lp(a) levels with the highest administered dose of 300 mg being the most effective treatment, as it produced a 77.8% reduction in Lp(a) levels from baseline. The treatment with APO(a)-Rx was safe and generally well-tolerated, as the most common adverse events were mild injection site reactions[38]. In a phase 2 trial of APO(a)-Rx, which was administered subcutaneously once a week for 12 wk in an ascending-dose design, similar reductions in Lp(a) levels of 66.8%-71.6% were observed[39]. In a phase 1/2a trial of the other developed agent, APO(a)-LRx, the highest administered dose of 40 mg provided a decrease of 92% in Lp(a) levels after six doses in healthy human volunteers. Both agents were also safe.[39] Thus, these new agents targeting the synthesis of Apo(a) may assist clinicians to effectively diminish Lp(a)-mediated cardiovascular risk.

A summary of the mechanisms of action of the aforementioned novel lipid-modifying therapies is shown in Table 1. In addition, the molecular pathways of action and effects of the aforementioned novel lipid-modifying therapies are shown in Figure 1.

ON THE HORIZON

Liver X receptors (LXRs) are members of the nuclear receptor superfamily of DNA-binding transcription factors and act as sensors of cholesterol homeostasis. LXRs mediate physiological responses to cellular and systemic cholesterol overload, including the upregulation of the reverse cholesterol transport (RCT), thus having cardioprotective effects against atherosclerosis. The development of drugs that stimulate LXRs have emerged as a new promising therapeutic intervention[40,41]. There are two isotypes of LXRs; LXRα and LXRβ. XL-652 or BMS-779788 is a partial LXR agonist with LXRβ selectivity. When tested in nonhuman primates, XL-652 appears to
Table 1  Mechanisms of action of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease

| Novel pharmacological agent | Mechanism of action |
|----------------------------|---------------------|
| Inclisiran                 | Small interfering RNA targeting the hepatic synthesis of PCSK9 |
| Bempedoic Acid             | Inhibition of hepatic ACL and activation of AMPK |
| Seladelpar                 | Selective PPAR-δ agonist |
| CSL-112                    | Reconstituted infusible human ApoA-I |
| Apabetalone                | Increase of ApoA-I transcription acting on bromodomain and extra-terminal domain (BET) protein 4 (BRD4) |
| Volanesorsen               | Human ASO inhibiting the expression of mRNA of the ApoC-III gene |
| APO(a)-Rx and APO(a)-LRx   | ASOs inhibiting the synthesis of the apolipoprotein (a) |
| XL-652                     | Partial LXR agonist with LXRβ selectivity |
| Allicin                    | Upregulation of ABCA1 expression in macrophage-derived foam cells |
| ACP-501                    | Recombinant human LCAT |

PCSK9: Proprotein convertase subtilisin/kexin type 9; ACL: Adenosine triphosphate-citrate lyase; AMPK: Adenosine monophosphate-activated protein kinase; PPAR: Peroxisome proliferator-activated receptor; ApoA-I: Apolipoprotein A-I; ASO: Antisense oligonucleotide; LXR: Liver X receptor; ABCA1: ATP-binding cassette transporter A1; LCAT: Lecithin-cholesterol acyltransferase.

have decreased lipogenic potential, as compared with a full pan agonist, but with similar potency in the induction of genes known to stimulate RCT\(^{42}\). XL-652 has also been proven to be safe enough to continue with clinical trials\(^{19}\).

Another important molecule involved in lipid homeostasis is ABCA1, which has a critical role in modulating efflux of tissue cholesterol and phospholipids into the RCT pathway, thus clearing excess cholesterol from macrophages and preventing atherosclerosis. There is a clinical entity, known as Tangier disease, which is caused by mutations of the ABCA1 gene leading to ABCA1 deficiency\(^{43}\). Allicin is a novel anti-atherosclerotic molecule with anti-oxidant and anti-inflammatory properties, which can be extracted from garlic. Allicin has been shown to reduce lipid accumulation through the upregulation of ABCA1 expression in macrophage-derived foam cells\(^{44}\). Furthermore, in a randomized, placebo-controlled, clinical trial, the oral administration of a garlic powder tablet, containing 1200 mg of allicin, twice daily for 3 mo, was shown to be superior to placebo in the prevention of carotid intima-media thickness progression in patients with CAD\(^{44}\). Another novel promising molecule, which has also been shown in animal studies to up-regulate ABCA1-mediated cholesterol efflux and retard atherosclerosis, is apigenin, a natural flavonoid compound\(^{46}\). Thus, given the above, allicin (and possibly apigenin) may be proven useful in the future for the management of CVD and may also potentially have a place in the treatment of patients with Tangier disease with some residual ABCA1 activity.

Lecithin-cholesterol acyltransferase (LCAT) is a key enzyme for the esterification of cholesteryl esters in plasma, promoting also the formation of HDL and enhancing RCT. Mutations in the human LCAT gene underlie either familial LCAT deficiency (FLD) or fish-eye disease (FED)\(^{47}\). In this regard, the infusion of recombinant human LCAT is a promising therapeutic option that remains to be explored. In a phase 1b, open-label, single-dose escalation study, a single intravenous infusion of a recombinant human LCAT (ACP-501) had an acceptable safety profile and led to significant dose-proportional increases of both LCAT and HDL-C, as well as to a favorable modification of HDL metabolism. The results of this study provide support for the use of recombinant human LCAT in future clinical trials in patient with CHD and/or FLD\(^{48}\). In a first-in-human treatment with enzyme replacement in FLD, ACP-501 infusion therapy improved the anemia, stabilized the renal function, transiently normalized plasma lipids, and favorably modified HDL metabolism. Moreover, ACP-501 therapy was safe and well-tolerated\(^{49}\). Hence, the results of these studies are encouraging and support continued development of the recombinant human LCAT therapy.

Last but not least, it should be noted that many other novel lipid-modifying therapies are being currently tested in ongoing trials. These therapies include medications that target protein asialoglycoprotein receptor 1, angiopoietin-related protein 4, desmocollin 1 and many other molecules playing significant roles in lipid homeostasis\(^{50,51}\).
Figure 1  Molecular pathways of action and effects of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. siRNA: Small interfering RNA; ACL: Adenosine triphosphate-citrate lyase; AMPK: Adenosine monophosphate-activated protein kinase; PPARs: Peroxisome proliferator-activated receptors; Apo: Apolipoprotein; ASO: Antisense oligonucleotide; PCSK9: Proprotein convertase subtilisin/kexin type 9; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; Lp(a): Lipoprotein (a); LXRs: Liver X receptors; LDL-C: Low-density lipoprotein cholesterol; CEC: Cholesterol efflux capacity.

CONCLUSION

It has been well established that despite the significant progress made in the management of CVD, there are still several unmet needs to be addressed. Currently, various lipid-modifying therapies are being evaluated in ongoing trials, targeting a number of different molecules involved in lipid homeostasis. There is optimism that some of these lipid-modifying therapies will be proven clinically beneficial and will eventually enter everyday clinical practice, hence enhancing the armamentarium for the optimal management of CV risk in dyslipidemic patients. Even if some of these drugs do not succeed in future trials, undoubtedly, we will still be a step forward towards a better understanding of the pathogenesis of atherosclerosis and to creating a better future for our patients, decreasing the risk of CVD.

REFERENCES

1 Heron M, Anderson RN. Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality. NCHS Data Brief 2016; 1-8 [PMID: 27598767]
2 Best AF, Haozous EA, Barrington de Gonzalez A, Chernyavsky P, Freedman ND, Hartje P, Thomas D, Rosenberg PS, Shields MS. Premature mortality projections in the USA through 2030: a modelling study. Lancet Public Health 2018; 3: e374-e384 [PMID: 30037721 DOI: 10.1016/S2468-2667(18)30114-2]
3 Baigent C, Keech A, Kearney PM, Blackwell L, Buch G, Pollicino C, Kirby A, Sjorjina T, Petro R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278 [PMID: 16214597 DOI: 10.1016/S0140-6736(05)67394-1]
4 Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005; 45: 89-118 [PMID: 15822172 DOI: 10.1146/annurev.pharmaco.45.120403.095748]
5 Sabatine MS, Giugliano RP, Kech AC, Honapour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722 [PMID: 28304224 DOI: 10.1056/NEJMoa1615664]
Schwartz GG, Steg PG, Szerek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tambry JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379: 2097-2107 DOI: 10.1056/NEJMoa1801174

Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012; 14: 1-10 DOI: 10.1007/s11883-011-0219-7

Perrouz V, Sangiorgi D, Buda S, Degli Esposti L. Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. Clinicoceo Outcomes Res 2016; 8: 649-655 DOI: 10.21875/COR.510792

Kosmas CE, Frishman WH. New and Emerging LDL Cholesterol-Lowering Drugs. Am J Ther 2015; 22: 234-241 DOI: 10.1097/MTI.0000000000000207

Kosmas CE, Muñoz Estrella A, Soursal A, Silverio D, Hilarion E, Montan PD, Guzman E. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Diseases 2018; 6 DOI: 10.3390/diseases6030063

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troqray RP, Turner T, Visseren FL, Wingard P, Wright RS, Kastelein JJ. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017; 376: 1340-1440 DOI: 10.1056/NEJMoa1615758

The Medicines Company. Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11). [accessed 2019 Mar 24]: In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03400800 ClinicalTrials.gov Identifier: NCT03400800

Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Kastelein JJ, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013; 62: 1154-1162 DOI: 10.1016/j.jacc.2013.05.050

Gutierrez MJ, Rosenblum NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014; 34: 676-683 DOI: 10.1161/ATVBAHA.113.302677

Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol 2015; 9: 295-304 DOI: 10.1016/j.jacl.2015.03.001

Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, Lafwan ND. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol 2016; 117: 1928-1933 DOI: 10.1016/j.amjcard.2016.03.043

Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 2016; 10: 556-567 DOI: 10.1016/j.jacl.2015.12.025

Goldberg AC. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia and high cardiovascular risk: the CLEAR Wisdom trial. ACC 2019 March 18; New Orleans, LA, 2019.

Xu P, Zhai Y, Wang J. The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. Int J Mol Sci 2018; 19 DOI: 10.3390/ijms19041260

Bays HE, Schwartz S, Littlejohn T, Kerzner J, Krauss RM, Roberts BK. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011; 96: 2889-2897 DOI: 10.1210/jc.2011-0061

Choi YJ, Roberts BK, Wang X, Geaney JC, Wang J. The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. J Clin Lipidol 2015; 9: 1928-1933 DOI: 10.1016/j.jacl.2015.03.001

Kosmas CE, Martinez I, Soursal A, Bouza KV, Campos FN, Torres V, Montan PD, Guzman E. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context 2018; 263: 1215225 DOI: 10.7537/dic.2125225

Tricoci P, D’Andrea DM, Gurbel PA, Zhai Y, Wang J. Effects of the Statin Intolerance Randomized Evaluation Study (STRESH) on Cardiovascular Outcomes. J Clin Lipidol 2015; 9: 556-567 DOI: 10.1016/j.jacl.2015.12.025

Kosmas CE, Frishman WH. New and Emerging LDL Cholesterol-Lowering Drugs. Am J Ther 2015; 22: 234-241 DOI: 10.1097/MTI.0000000000000207

Michael Gibson C, Tricoci P, Buda S, Degli Esposti L. Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. Clinicoceo Outcomes Res 2016; 8: 649-655 DOI: 10.21875/COR.510792

Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJ, Taylor A, Borgan M, Nissen SE. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011; 57: 376-387 DOI: 10.1016/j.jacc.2011.03.001

https://clinicaltrials.gov/ct2/show/NCT03473223 ClinicalTrials.gov Identifier: NCT03473223

McLure KG, Giesner EM, Tsouwla L, Kerenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NC, Wagner GS, Hansen HC, Young PR, RVX-208, an inducer of Apo-A-I in humans, is a BET bromodomain antagonist. PLoS One 2013; 8: e63190 DOI: 10.1371/journal.pone.0063190

Kosmas CE et al. Novel lipid therapies in CVD
ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Trial. 2009; Curr Opin Endocrinol Diabetes Obes: 163-171.

Hegele RA. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2015; 22: 119-125 [PMID: 25692924 DOI: 10.1097/MED.0000000000000136]

Gaudet D, Alexander VJ, Baker BF, Brissin D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med 2015; 373: 438-447 [PMID: 26222559 DOI: 10.1056/NEJMoa1400283]

Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q, Miller YI, Witztum JL, Tsikrikas S. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res 2016; 57: 706-713 [PMID: 26848137 DOI: 10.1194/jlr.M066399]

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM. Anti-CIII-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care 2017; 39: 1408-1415 [PMID: 27271183 DOI: 10.2337/dc17-0126]

Kepley CT, Naranjo A, O'Dea L, Stevenson M. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther 2018; 16: 537-546 [PMID: 29889586 DOI: 10.1080/14779072.2018.1487290]

Saeed A, Virani SS. Lipoprotein(a) and cardiovascular disease: current status and future directions for an enigmatic lipidoprotein. Front Biosci (Landmark Ed) 2018; 23: 1099-1112 [PMID: 28930591]

Hegele RA, Tsikrikas S. Lipid-Lowering Agents. Circ Res 2019; 124: 386-404 [PMID: 30702996 DOI: 10.1161/CIRCRESAHA.118.313171]

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL. Antisense therapy targeting apolipoprotein(a) is randomized, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386: 1472-1483 [PMID: 26210642 DOI: 10.1016/S0140-6736(15)6251-2]

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsikrikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388: 2239-2253 [PMID: 27665230 DOI: 10.1016/S0140-6736(16)3099-1]

Ma Z, Deng C, Hu W, Zhou J, Fan C, Di S, Liu D, Yang Y, Wang D. Liver X Receptors and their Agonists: Targeting for Cholesterol Homeostasis and Cardiovascular Diseases. Curr Issues Mol Biol 2017; 22: 41-64 [PMID: 27669066 DOI: 10.21775/cimb.022.041]

Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 2015; 242: 29-36 [PMID: 26164157 DOI: 10.1016/j.atherosclerosis.2015.06.042]

Vinson NK, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsikrikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388: 2239-2253 [PMID: 27665230 DOI: 10.1016/S0140-6736(16)3099-1]

Ma Z, Deng C, Hu W, Zhou J, Fan C, Di S, Liu D, Yang Y, Wang D. Liver X Receptors and their Agonists: Targeting for Cholesterol Homeostasis and Cardiovascular Diseases. Curr Issues Mol Biol 2017; 22: 41-64 [PMID: 27669066 DOI: 10.21775/cimb.022.041]

Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 2015; 242: 29-36 [PMID: 26164157 DOI: 10.1016/j.atherosclerosis.2015.06.042]

Kirchberger TG, Martin R, Sleph P, Grimm D, Liu X, Lupisella J, Smalley J, Narayanan R, Xie Y, Orozjukow J, Cantor GH, Mohan R, Rick E. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates. J Pharmacol Exp Ther 2015; 352: 305-314 [PMID: 25467132 DOI: 11.124/pet.114.219923]

Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta 2000; 1529: 321-330 [PMID: 1111099 DOI: 10.1016/S0005-2760(00)01788-3]

Lin XL, Hu HJ, Liu YJ, Hu XM, Fan XJ, Zhou WW, Pan YQ, Zhou WQ, Peng MW, Gu CH. Allicin induces the upregulation of ABCA1 expression via PPARα/LXRα signaling in THP-1 macrophage-derived foam cells. Int J Mol Med 2017; 39: 1452-1460 [PMID: 28484041 DOI: 10.3892/ijmm.2017.2949]

Mahdavi-Roshan M, Zahedehvar M, Mohammad-Zadeh A, Sanati HR, Shakarian F, Firoozi A, Kiani R, Nasrollahzadeh J. Effect of garlic powder tablet on carotid intima-media thickness in patients with coronary artery disease: a preliminary randomized controlled trial. Nutr Health 2013; 22: 143-155 [PMID: 25573347 DOI: 10.1177/0260106015463446]

Ren K, Jiang T, Zhou HF, Liang Y, Zhao GJ. Apigenin Retards Atherogenesis by Promoting ABCA1-Mediated Cholesterol Efflux and Suppressing Inflammation. Cell Physiol Biochem 2018; 47: 2170-2184 [PMID: 29975943 DOI: 10.1159/000491528]

Roussel X, Vaisman B, Aman M, Sethi AA, Remaley AT. Lechinin: cholesterol acyltransferase—from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009; 16: 163-171 [PMID: 19306528]

Shamburek RD, Bakker-Arkema R, Shamburek AM, Freeman LA, Aman MJ, Auerbach B, Krause BR, Honan R, Adelman SJ, Collins HJ, Sampson M, Wolska A, Remaley AT. Safety and Tolerability of ACP-501, a Recombinant Human Lechinin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose
49 Shamburek RD, Bakker-Arkema R, Auerbach BJ, Krause BR, Homan R, Amar MJ, Freeman LA, Remaley AT. Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement. J Clin Lipidol 2016; 10: 356-367 [PMID: 27055967 DOI: 10.1016/j.jacl.2015.12.007]

50 Tang WH, Hazen SL. Atherosclerosis in 2016: Advances in new therapeutic targets for atherosclerosis. Nat Rev Cardiol 2017; 14: 71-72 [PMID: 28094270 DOI: 10.1038/nrcardio.2016.216]

51 Choi HY, Ruel I, Malina A, Garrod DR, Oda MN, Pellestor J, Schwertani A, Genest J. Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. Eur Heart J 2018; 39: 1194-1202 [PMID: 29106519 DOI: 10.1093/eurheartj/ehx340]
